Cartesian Therapeutics (RNAC) Receivables - Other (2020 - 2024)
Cartesian Therapeutics (RNAC) has disclosed Receivables - Other for 5 consecutive years, with $980000.0 as the latest value for Q3 2024.
- On a quarterly basis, Receivables - Other fell 47.73% to $980000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $980000.0, a 47.73% decrease, with the full-year FY2023 number at $3.0 million, down 5.72% from a year prior.
- Receivables - Other was $980000.0 for Q3 2024 at Cartesian Therapeutics, down from $3.5 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $3.5 million in Q2 2024 to a low of $100000.0 in Q3 2021.
- A 5-year average of $1.7 million and a median of $1.5 million in 2020 define the central range for Receivables - Other.
- Peak YoY movement for Receivables - Other: crashed 93.33% in 2021, then soared 229.1% in 2024.
- Cartesian Therapeutics' Receivables - Other stood at $1.0 million in 2020, then tumbled by 90.0% to $100000.0 in 2021, then skyrocketed by 3062.0% to $3.2 million in 2022, then fell by 5.72% to $3.0 million in 2023, then crashed by 67.13% to $980000.0 in 2024.
- Per Business Quant, the three most recent readings for RNAC's Receivables - Other are $980000.0 (Q3 2024), $3.5 million (Q2 2024), and $2.4 million (Q1 2024).